Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Current Deferred Revenue (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Current Deferred Revenue for 3 consecutive years, with $167000.0 as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 1.83% to $167000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $167000.0 through Dec 2025, up 1.83% year-over-year, with the annual reading at $167000.0 for FY2025, 1.83% up from the prior year.
  • Current Deferred Revenue hit $167000.0 in Q4 2025 for Connect Biopharma Holdings, up from $165000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $13.3 million in Q4 2023 to a low of $164000.0 in Q4 2024.
  • Historically, Current Deferred Revenue has averaged $2.4 million across 3 years, with a median of $164500.0 in 2024.
  • Biggest five-year swings in Current Deferred Revenue: crashed 98.77% in 2024 and later rose 1.83% in 2025.
  • Year by year, Current Deferred Revenue stood at $13.3 million in 2023, then plummeted by 98.77% to $164000.0 in 2024, then grew by 1.83% to $167000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for CNTB at $167000.0 in Q4 2025, $165000.0 in Q3 2025, and $164000.0 in Q2 2025.